Bank of America Corp DE Lowers Position in Grifols, S.A. (NASDAQ:GRFS)

Bank of America Corp DE lowered its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 19.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,040,435 shares of the biotechnology company's stock after selling 961,587 shares during the quarter. Bank of America Corp DE owned approximately 0.59% of Grifols worth $30,061,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in Grifols in the 4th quarter valued at $14,434,000. Credit Industriel ET Commercial acquired a new position in Grifols in the fourth quarter valued at approximately $4,537,000. Brandes Investment Partners LP raised its holdings in Grifols by 3.0% in the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock valued at $152,491,000 after buying an additional 592,096 shares during the period. Barclays PLC increased its holdings in Grifols by 381.2% in the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock valued at $5,261,000 after purchasing an additional 469,401 shares during the last quarter. Finally, Cigogne Management SA acquired a new position in Grifols during the 4th quarter worth about $1,778,000.

Grifols Trading Down 0.7%

Shares of GRFS traded down $0.05 on Thursday, hitting $8.14. 71,228 shares of the stock traded hands, compared to its average volume of 1,161,484. The firm has a market capitalization of $5.59 billion, a P/E ratio of 6.96 and a beta of 0.44. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 1 year low of $5.79 and a 1 year high of $9.96. The stock's 50 day moving average is $7.31 and its two-hundred day moving average is $7.62.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. StockNews.com upgraded Grifols from a "hold" rating to a "buy" rating in a report on Thursday, May 15th. Morgan Stanley initiated coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.